

Karin J Metzner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9508963/publications.pdf>

Version: 2024-02-01

116
papers

3,797
citations

136950

32
h-index

144013

57
g-index

121
all docs

121
docs citations

121
times ranked

4618
citing authors

#	ARTICLE	IF	CITATIONS
1	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. <i>Viruses</i> , 2022, 14, 406.	3.3	1
2	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	9
3	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. <i>Journal of Infectious Diseases</i> , 2022, 226, 1057-1068.	4.0	2
4	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. <i>Viruses</i> , 2022, 14, 784.	3.3	2
5	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	3
6	Systematic HIV-1 promoter targeting with CRISPR/dCas9-VPR reveals optimal region for activation of the latent provirus. <i>Journal of General Virology</i> , 2022, 103, .	2.9	3
7	Quantification of transgene expression in GSH AAVS1 with a novel CRISPR/Cas9-based approach reveals high transcriptional variation. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 107-118.	4.1	2
8	Women in the European Virus Bioinformatics Center. <i>Viruses</i> , 2022, 14, 1522.	3.3	1
9	Technologies for HIV-1 drug resistance testing: inventory and needs. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 222-228.	3.8	12
10	Preclinical Evaluation of a Novel TALEN Targeting <i>CCR5</i> Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection. <i>Biotechnology Journal</i> , 2021, 16, e2000023.	3.5	18
11	Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naïve HIV-1-infected individuals in Cameroon. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 124-129.	3.0	5
12	V-pipe: a computational pipeline for assessing viral genetic diversity from high-throughput data. <i>Bioinformatics</i> , 2021, 37, 1673-1680.	4.1	61
13	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab046.	0.9	0
14	A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. <i>Viruses</i> , 2021, 13, 404.	3.3	3
15	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. <i>JCI Insight</i> , 2021, 6, .	5.0	7
16	Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. <i>HIV Medicine</i> , 2021, 22, 346-359.	2.2	2
17	Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naïve Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact. <i>Journal of Infectious Diseases</i> , 2020, 221, 1584-1597.	4.0	40
18	Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. <i>Viruses</i> , 2020, 12, 1330.	3.3	9

#	ARTICLE	IF	CITATIONS
19	Reversal of T Cell Exhaustion in Chronic HCV Infection. <i>Viruses</i> , 2020, 12, 799.	3.3	14
20	Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3319-3326.	3.0	9
21	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	2.1	7
22	Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. <i>Scientific Reports</i> , 2020, 10, 16060.	3.3	16
23	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. <i>Viruses</i> , 2020, 12, 1241.	3.3	3
24	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	12.8	5
25	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. <i>PLoS Biology</i> , 2020, 18, e3001010.	5.6	4
26	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™ HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	8.4	23
27	EBV renders B cells susceptible to HIV-1 in humanized mice. <i>Life Science Alliance</i> , 2020, 3, e202000640.	2.8	22
28	HIV-1 promoter is gradually silenced when integrated into <i>BACH2</i> in Jurkat T-cells. <i>PeerJ</i> , 2020, 8, e10321.	2.0	2
29	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
30	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
31	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
32	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
33	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
34	Long-term experimental evolution of HIV-1 reveals effects of environment and mutational history. , 2020, 18, e3001010.		0
35	Title is missing!. , 2020, 17, e1003421.		0
36	Title is missing!. , 2020, 17, e1003421.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 17, e1003421.		0
38	Title is missing!. , 2020, 17, e1003421.		0
39	Title is missing!. , 2020, 17, e1003421.		0
40	Title is missing!. , 2020, 17, e1003421.		0
41	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
42	Parallel Evolution of HIV-1 in a Long-Term Experiment. Molecular Biology and Evolution, 2019, 36, 2400-2414.	8.9	25
43	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	4.0	27
44	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	4.0	24
45	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clinical Infectious Diseases, 2019, 69, 1489-1497.	5.8	19
46	Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16. Journal of Antimicrobial Chemotherapy, 2018, 73, 1917-1929.	3.0	16
47	Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV Medicine, 2018, 19, 420-425.	2.2	12
48	No Effect of Pegylated Interferon- α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. Journal of Infectious Diseases, 2018, 217, 1883-1888.	4.0	10
49	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	27.8	47
50	Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. Scientific Reports, 2018, 8, 10204.	3.3	8
51	Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study. HIV Medicine, 2018, 19, 572-577.	2.2	16
52	In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells. Molecular and Cellular Proteomics, 2017, 16, S108-S123.	3.8	18
53	Mining for pairs: shared clinic visit dates identify steady <sc>HIV</sc>-positive partnerships. HIV Medicine, 2017, 18, 667-676.	2.2	2
54	MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. Journal of Virological Methods, 2017, 240, 7-13.	2.1	49

#	ARTICLE	IF	CITATIONS
55	Unravelling HIV-1 Latency, One Cell at a Time. <i>Trends in Microbiology</i> , 2017, 25, 932-941.	7.7	17
56	Reply to correspondence "Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process" by Gonzalez et al., <i>Retrovirology</i> 2017. <i>Retrovirology</i> , 2017, 14, 14.	2.0	3
57	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	6.0	16
58	Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples. <i>Microbiome</i> , 2017, 5, 94.	11.1	59
59	Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. <i>PLoS Pathogens</i> , 2017, 13, e1006255.	4.7	27
60	A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing. <i>PLoS ONE</i> , 2016, 11, e0146687.	2.5	15
61	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. <i>Scientific Reports</i> , 2016, 6, 24157.	3.3	21
62	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016, 13, 62.	2.0	45
63	A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations. <i>Journal of Molecular Biology</i> , 2016, 428, 238-250.	4.2	25
64	Commentary: HIV Whole-Genome Sequencing Now: Answering Still-Open Questions. <i>Journal of Clinical Microbiology</i> , 2016, 54, 834-835.	3.9	8
65	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. <i>Clinical Microbiology and Infection</i> , 2016, 22, 191-200.	6.0	27
66	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	2.2	5
67	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	2.5	18
68	A Framework for Inferring Fitness Landscapes of Patient-Derived Viruses Using Quasispecies Theory. <i>Genetics</i> , 2015, 199, 191-203.	2.9	28
69	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.9	20
70	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 930-940.	3.0	102
71	Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 922-925.	3.0	22
72	HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages. <i>PLoS ONE</i> , 2015, 10, e0132127.	2.5	15

#	ARTICLE	IF	CITATIONS
73	Efficacy of leadâ€”in silibinin and subsequent triple therapy in difficultâ€”toâ€”treat <scp>HIV</scp>/hepatitis <scp>C</scp> virusâ€”coinfecting patients. <i>HIV Medicine</i> , 2014, 15, 625-630.	2.2	13
74	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. <i>Nucleic Acids Research</i> , 2014, 42, e115-e115.	14.5	126
75	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. <i>Aids</i> , 2014, 28, 2231-2239.	2.2	20
76	Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-Î±. <i>Rna</i> , 2014, 20, 61-75.	3.5	46
77	An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. <i>Journal of Virological Methods</i> , 2014, 204, 31-37.	2.1	31
78	Recovering networks from distance data. <i>Machine Learning</i> , 2013, 92, 251-283.	5.4	1
79	Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure. <i>Journal of Infectious Diseases</i> , 2013, 207, 893-897.	4.0	53
80	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1102-1112.	4.0	35
81	Probing of viral diversity by global haplotype prediction. , 2013, , .		0
82	Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. <i>PLoS ONE</i> , 2013, 8, e74249.	2.5	55
83	Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. <i>Frontiers in Microbiology</i> , 2012, 3, 329.	3.5	204
84	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. <i>Retrovirology</i> , 2012, 9, 27.	2.0	39
85	Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. <i>Journal of Clinical Virology</i> , 2011, 50, 156-161.	3.1	47
86	Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1â€”infected Eritrean Immigrant. <i>Emerging Infectious Diseases</i> , 2011, 17, 1966-1968.	4.3	9
87	Reappearance of Minority K103N HIV-1 Variants after Interruption of ART Initiated during Primary HIV-1 Infection. <i>PLoS ONE</i> , 2011, 6, e21734.	2.5	9
88	In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. <i>Journal of Virological Methods</i> , 2011, 171, 329-338.	2.1	16
89	A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication. <i>BMC Biotechnology</i> , 2011, 11, 4.	3.3	14
90	Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1327.	7.4	315

#	ARTICLE	IF	CITATIONS
91	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1271-1279.	5.8	84
92	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. <i>Journal of Virological Methods</i> , 2010, 165, 151-160.	2.1	33
93	The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro. <i>Antiviral Research</i> , 2010, 86, 312-315.	4.1	6
94	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. <i>PLoS ONE</i> , 2010, 5, e13310.	2.5	84
95	Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1063-1071.	4.0	51
96	Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and Adherent Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 239-247.	5.8	188
97	Comparison of G-to-A Mutation Frequencies Induced by APOBEC3 Proteins in H9 Cells and Peripheral Blood Mononuclear Cells in the Context of Impaired Processivities of Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants. <i>Journal of Virology</i> , 2008, 82, 6536-6545.	3.4	15
98	Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA. <i>Aids</i> , 2008, 22, 1577-1582.	2.2	10
99	Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. <i>Aids</i> , 2007, 21, 703-711.	2.2	36
100	Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 377-385.	2.1	12
101	Molecular characterisation of Lac s 1, the major allergen from lettuce (<i>Lactuca sativa</i>). <i>Molecular Immunology</i> , 2007, 44, 2820-2830.	2.2	35
102	Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. <i>Retrovirology</i> , 2006, 3, 97.	2.0	14
103	Inhibition of drug-resistant HIV-1 by RNA interference. <i>Antiviral Research</i> , 2006, 69, 1-8.	4.1	33
104	Persistence of drug-resistant HIV-1 and possible implications for antiretroviral therapy. <i>Future Virology</i> , 2006, 1, 377-391.	1.8	5
105	Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2612-2614.	3.9	104
106	Detection and significance of minority quasispecies of drug-resistant HIV-1. <i>Journal of HIV Therapy</i> , 2006, 11, 74-81.	0.6	7
107	Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. <i>Journal of General Virology</i> , 2005, 86, 3375-3384.	2.9	12
108	Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. <i>Aids</i> , 2005, 19, 1819-1825.	2.2	102

#	ARTICLE	IF	CITATIONS
109	A Truncated Form of Nef Selected during Pathogenic Reversion of Simian Immunodeficiency Virus SIVmac239I ^{nef} Increases Viral Replication. <i>Journal of Virology</i> , 2003, 77, 1245-1256.	3.4	45
110	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. <i>Journal of Infectious Diseases</i> , 2003, 188, 1433-1443.	4.0	121
111	Direct Measurement of CD8+ T Cell Responses in Macaques Infected with Simian Immunodeficiency Virus. <i>Virology</i> , 2000, 272, 347-356.	2.4	33
112	Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes and Protection Against Challenge in Rhesus Macaques Immunized with a Live Attenuated Simian Immunodeficiency Virus Vaccine. <i>Virology</i> , 2000, 266, 203-210.	2.4	41
113	Effects of in Vivo Cd8+ T Cell Depletion on Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine. <i>Journal of Experimental Medicine</i> , 2000, 191, 1921-1932.	8.5	147
114	Molecular cloning, expression and characterization of Pru a 1, the major cherry allergen. <i>Molecular Immunology</i> , 1997, 34, 619-629.	2.2	101
115	HIV suppression by interleukin-16. <i>Nature</i> , 1995, 378, 563-563.	27.8	283
116	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLI [™] HIV Trial). <i>Frontiers in Virology</i> , 0, 2, .	1.4	0